National Academy of Agricultural Sciences (NAAS)
|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
The present study investigated the effect of acetylsalicylic acid, an antiaggregant, on postoperative atrial fibrillation after coronary artery bypass surgery. Atrial fibrillation is a problem that affects mortality and morbidity rates after coronary surgery and prolongs hospital stay. Between January 2011 and October 2018, 722 coronary bypass surgery operations were performed. The patients were randomly divided into two groups as drug group (Group I; n=356) and control group (Group II; n=366). In Group I, the patients take to the acetylsalicylic acid (300 mg) without stopping up to 3 days before coronary bypass surgery. In Group II, the patients did not receive acetylsalicylic acid before surgery. Atrial fibrillation incidence rates were recorded retrospectively between 2 days and 4 weeks after the operation. Atrial fibrillation was seen in 21 (5.8%) patients in the Group I and 102 (27, 8 %) patients in the Group II had postoperative atrial fibrillation (p < 0.05). Intensive care unit and hospital stay were shorter in the drug group than the control group (p <0.05). In addition, hospital treatment costs were lower in the drug group (p <0.05). These results supported that acetylsalicylic acid is effective in preventing atrial fibrillation. Besides, acetylsalicylic acid treatment until operation day reduces hospital costs and length of stay in hospital, after the coronary artery bypasses grafting.
Citations |
 |
 |
 |
 |
